Pharming Group N.V. (PHAR) Thursday said the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja to treat individuals aged 12 years and older with activated phosphoinositide 3-kinase delta syndrome (APDS), a genetic disorder that impairs the immune system.
The MHRA evaluated the Marketing authorization Application (MAA) for leniolisib through the International Recognition Procedure (IRP) pathway on the basis of the U.S. Food and Drug Administration approval received in March 2023, the company said in a statement.
The drug is under evaluation by the National Institute for Health and Care Excellence (NICE) regarding reimbursement within the National Health Service (NHS) in England.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.